Session: 101. Red Cells and Erythropoiesis, Excluding Iron: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research, Genetic Disorders, Diseases, Metabolism, Biological Processes, Molecular biology
Aim: To explore the effects of decreased PK activity on glucose metabolism of HX RBCs using ex vivo glucose tracing.
Methods: Four healthy controls (HCs) and four patients with HX caused by a GoF variant in PIEZO1 were studied. PIEZO1 variants were: c.1792G>A p.(Val598Met); c.7367G>A p.(Arg2456His) (2 relatives); and c.7483-7488dupCTGGAG p.(Leu2495_Glu2496dup). RBCs were purified and incubated at 37 ⁰C in RPMI medium for 30 minutes. Then, medium was changed to glucose-free RPMI supplemented with 13C6-carbon labeled glucose and RBCs were incubated up to 360 minutes. RBCs and medium samples were collected prior to medium change and at 0, 30, 60, 120, 240, and 360 minutes. Metabolites were extracted from pelleted RBCs and medium using methanol and measured using ultra high pressure liquid chromatography coupled to high resolution mass spectrometry. Peaks were integrated using TraceFindr software and unpaired t-tests with Welch’s correction were performed in GraphPad Prism.
Results: After changing the medium to glucose-free medium supplemented with 13C6-carbon labeled glucose, negligible amounts of unlabeled glucose remained. Hence, only 13C6-carbon labeled glucose was taken up and metabolized by the RBCs. Over time, we observed a decrease in the level of unlabeled and an increase in the level of 13C6-carbon labeled glycolytic metabolites. In HCs, unlabeled glycolytic metabolites were almost completely replaced by 13C6-carbon labeled metabolites after 360 minutes. This turnover was already observed after 240 minutes in HX RBCs. HX RBCs also demonstrated increased production of 13C6-carbon labeled pyruvate (HC 11.6 µM vs HX 25.6 µM, p=0.04), intracellular lactate (HC 98.6 µM vs HX 302.0 µM, p=0.002) and secreted lactate (HC 279.3 µM vs HX 910.8 µM, p<0.0001), the end products of glycolysis. These results indicate enhanced glycolytic flux. Furthermore, we observed increased production of 13C6-carbon labeled glucose-6-phosphate in HX RBCs compared to HCs (HC 5.6 µM vs HX 8.4 µM, not significant), which could indicate a slightly elevated glucose uptake.
Conclusion: We used glucose tracing to study glycolytic flux in RBCs from healthy donors and patients with HX due to a PIEZO1 GoF defect. We demonstrate that RBCs from HX patients show a faster turnover of unlabeled glycolytic metabolites, as well as increased production of 13C6-carbon labeled end products of glycolysis. These results strongly suggest that glycolytic flux is enhanced in HX patients. Glycolysis might be increased in HX patients to produce more ATP to counteract the disturbed ion balance. Interestingly, this enhanced glycolytic flux occurs in presence of the previously reported decrease in PK activity. Further studies are warranted to establish if and how increased mechanosensitivity and intracellular calcium levels are associated with enhanced glycolysis, and if the increased reticulocyte count typically seen in HX patients plays a role. Notably, small molecule activators of PK are currently being tested in various hereditary anemias and could potentially also have a beneficial effect for HX RBCs by enhancing glycolytic flux, and thereby ATP production, even further. Finally, the results of this study suggest that glucose tracing is a useful tool to better understand HX (patho)physiology and it has the potential to study the effect of PK activation therapy in patients with HX and other hereditary red blood cell disorders.
Disclosures: De Wilde: Agios Pharmaceuticals: Research Funding. Rab: Pfizer: Research Funding; RR Mechatronics: Research Funding; Agios: Research Funding. van Wijk: RR Mechatronics: Consultancy; Pfizer: Research Funding; Agios Pharmaceuticals: Research Funding.
See more of: Oral and Poster Abstracts